In a TNBC murine model, doxorubicin/cyclophosphamide regimen was able to effectively inhibit tumor growth, increase the survival benefit, promote infiltrating of CD8+ T cells and suppress the suppressor molecules PD-L1 expression (128). Here, CD274 is linked to neoplasm.